Cargando…

COVID-19 Vaccination in Patients with Severe Asthma on Biologic Treatment: Safety, Tolerability, and Impact on Disease Control

Background: COVID-19 vaccination has been recommended for severe asthmatics. We aimed to evaluate the safety, tolerability, and impact on disease control and patient’s quality of life of the mRNA SARS-CoV-2/COVID-19 vaccine in severe asthma patients regarding biologic treatment. Methods: Severe asth...

Descripción completa

Detalles Bibliográficos
Autores principales: Caminati, Marco, Guarnieri, Gabriella, Batani, Veronica, Scarpieri, Elena, Finocchiaro, Anita, Chieco-Bianchi, Fulvia, Senna, Gianenrico, Vianello, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8402597/
https://www.ncbi.nlm.nih.gov/pubmed/34451978
http://dx.doi.org/10.3390/vaccines9080853
_version_ 1783745828132749312
author Caminati, Marco
Guarnieri, Gabriella
Batani, Veronica
Scarpieri, Elena
Finocchiaro, Anita
Chieco-Bianchi, Fulvia
Senna, Gianenrico
Vianello, Andrea
author_facet Caminati, Marco
Guarnieri, Gabriella
Batani, Veronica
Scarpieri, Elena
Finocchiaro, Anita
Chieco-Bianchi, Fulvia
Senna, Gianenrico
Vianello, Andrea
author_sort Caminati, Marco
collection PubMed
description Background: COVID-19 vaccination has been recommended for severe asthmatics. We aimed to evaluate the safety, tolerability, and impact on disease control and patient’s quality of life of the mRNA SARS-CoV-2/COVID-19 vaccine in severe asthma patients regarding biologic treatment. Methods: Severe asthmatic patients regularly managed by two big allergy and respiratory referral centers were offered to undergo Pfizer COVID 19 vaccination at the hospital site. Patients filled in an adverse events questionnaire after the first and second dose, as well as the Asthma Control Test (ACT) and Asthma Quality of Life Questionnaire (AQLQ). Results: Overall, 253 patients were vaccinated; only 16 patients refused. No serious events were detected. Less than 20% of patients reported side effects, most of which were classified as very common side effects. No differences were reported according to the ongoing biologic drug. A significant improvement in both ACT and AQLQ was observed between the first and the second dose administration. Conclusions: Our data confirm the optimal safety and tolerability profile of mRNA SARS- CoV-2/COVID-19 in severe asthma patients on biologic treatment, as well as their positive attitude towards COVID-19 vaccination. The negligible proportion of patients reporting side effects and the absence of asthma exacerbations are relevant to support the COVID-19 vaccination campaign in severe asthma patients worldwide.
format Online
Article
Text
id pubmed-8402597
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-84025972021-08-29 COVID-19 Vaccination in Patients with Severe Asthma on Biologic Treatment: Safety, Tolerability, and Impact on Disease Control Caminati, Marco Guarnieri, Gabriella Batani, Veronica Scarpieri, Elena Finocchiaro, Anita Chieco-Bianchi, Fulvia Senna, Gianenrico Vianello, Andrea Vaccines (Basel) Article Background: COVID-19 vaccination has been recommended for severe asthmatics. We aimed to evaluate the safety, tolerability, and impact on disease control and patient’s quality of life of the mRNA SARS-CoV-2/COVID-19 vaccine in severe asthma patients regarding biologic treatment. Methods: Severe asthmatic patients regularly managed by two big allergy and respiratory referral centers were offered to undergo Pfizer COVID 19 vaccination at the hospital site. Patients filled in an adverse events questionnaire after the first and second dose, as well as the Asthma Control Test (ACT) and Asthma Quality of Life Questionnaire (AQLQ). Results: Overall, 253 patients were vaccinated; only 16 patients refused. No serious events were detected. Less than 20% of patients reported side effects, most of which were classified as very common side effects. No differences were reported according to the ongoing biologic drug. A significant improvement in both ACT and AQLQ was observed between the first and the second dose administration. Conclusions: Our data confirm the optimal safety and tolerability profile of mRNA SARS- CoV-2/COVID-19 in severe asthma patients on biologic treatment, as well as their positive attitude towards COVID-19 vaccination. The negligible proportion of patients reporting side effects and the absence of asthma exacerbations are relevant to support the COVID-19 vaccination campaign in severe asthma patients worldwide. MDPI 2021-08-04 /pmc/articles/PMC8402597/ /pubmed/34451978 http://dx.doi.org/10.3390/vaccines9080853 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Caminati, Marco
Guarnieri, Gabriella
Batani, Veronica
Scarpieri, Elena
Finocchiaro, Anita
Chieco-Bianchi, Fulvia
Senna, Gianenrico
Vianello, Andrea
COVID-19 Vaccination in Patients with Severe Asthma on Biologic Treatment: Safety, Tolerability, and Impact on Disease Control
title COVID-19 Vaccination in Patients with Severe Asthma on Biologic Treatment: Safety, Tolerability, and Impact on Disease Control
title_full COVID-19 Vaccination in Patients with Severe Asthma on Biologic Treatment: Safety, Tolerability, and Impact on Disease Control
title_fullStr COVID-19 Vaccination in Patients with Severe Asthma on Biologic Treatment: Safety, Tolerability, and Impact on Disease Control
title_full_unstemmed COVID-19 Vaccination in Patients with Severe Asthma on Biologic Treatment: Safety, Tolerability, and Impact on Disease Control
title_short COVID-19 Vaccination in Patients with Severe Asthma on Biologic Treatment: Safety, Tolerability, and Impact on Disease Control
title_sort covid-19 vaccination in patients with severe asthma on biologic treatment: safety, tolerability, and impact on disease control
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8402597/
https://www.ncbi.nlm.nih.gov/pubmed/34451978
http://dx.doi.org/10.3390/vaccines9080853
work_keys_str_mv AT caminatimarco covid19vaccinationinpatientswithsevereasthmaonbiologictreatmentsafetytolerabilityandimpactondiseasecontrol
AT guarnierigabriella covid19vaccinationinpatientswithsevereasthmaonbiologictreatmentsafetytolerabilityandimpactondiseasecontrol
AT bataniveronica covid19vaccinationinpatientswithsevereasthmaonbiologictreatmentsafetytolerabilityandimpactondiseasecontrol
AT scarpierielena covid19vaccinationinpatientswithsevereasthmaonbiologictreatmentsafetytolerabilityandimpactondiseasecontrol
AT finocchiaroanita covid19vaccinationinpatientswithsevereasthmaonbiologictreatmentsafetytolerabilityandimpactondiseasecontrol
AT chiecobianchifulvia covid19vaccinationinpatientswithsevereasthmaonbiologictreatmentsafetytolerabilityandimpactondiseasecontrol
AT sennagianenrico covid19vaccinationinpatientswithsevereasthmaonbiologictreatmentsafetytolerabilityandimpactondiseasecontrol
AT vianelloandrea covid19vaccinationinpatientswithsevereasthmaonbiologictreatmentsafetytolerabilityandimpactondiseasecontrol